2023 World Conference on Lung Cancer (Posters)-EP07.04. Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC)

EP07.04. Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

Back to course

Pdf Summary

A study conducted by Dr. Laura Sellmer at LMU Hospital in Germany looked at the relationship between immune cell states and survival in patients with stage I non-small cell lung cancer (NSCLC) who underwent surgery. The study utilized immune transcriptomics in tumor and lymph nodes, as well as assessment of immune dysfunction using the TIDE algorithm and digital flow cytometry based on bulk RNAseq data via CIBERSORT. The researchers found that immune cell types differed significantly between patients with and without immune dysfunction in stage I NSCLC, with NK-cells in the tumor and N1 lymph nodes showing the most significant differences. In stage III/IV NSCLC, CD8-cells in affected lymph nodes and N2 lymph nodes were found to be correlated with TIDE, a measure of immune dysfunction. Additionally, markers of immune cell exhaustion, such as TIM-3 expression, were found to be associated with immune dysfunction and overall survival in NSCLC. Interestingly, these markers showed different patterns in stage I versus stage III/IV NSCLC. The study concluded that immune cell exhaustion markers are associated with overall survival in NSCLC, and their importance increases with higher tumor stages. The research was conducted by Dr. Laura Sellmer and her colleagues at LMU Hospital, with contributions from the Tufman Group, the Weigert Group, and the Department of Thoracic Surgery and Pathology.

Asset Subtitle

Laura Sellmer

Meta Tag

Speaker Laura Sellmer

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

immune cell states

survival

stage I NSCLC

immune dysfunction

TIDE algorithm

NK-cells

CD8-cells

N2 lymph nodes

immune cell exhaustion

overall survival